508 related articles for article (PubMed ID: 28069058)
1. Endosulfine-alpha inhibits membrane-induced α-synuclein aggregation and protects against α-synuclein neurotoxicity.
Ysselstein D; Dehay B; Costantino IM; McCabe GP; Frosch MP; George JM; Bezard E; Rochet JC
Acta Neuropathol Commun; 2017 Jan; 5(1):3. PubMed ID: 28069058
[TBL] [Abstract][Full Text] [Related]
2. Effects of impaired membrane interactions on α-synuclein aggregation and neurotoxicity.
Ysselstein D; Joshi M; Mishra V; Griggs AM; Asiago JM; McCabe GP; Stanciu LA; Post CB; Rochet JC
Neurobiol Dis; 2015 Jul; 79():150-63. PubMed ID: 25931201
[TBL] [Abstract][Full Text] [Related]
3. Two C-terminal sequence variations determine differential neurotoxicity between human and mouse α-synuclein.
Landeck N; Strathearn KE; Ysselstein D; Buck K; Dutta S; Banerjee S; Lv Z; Hulleman JD; Hindupur J; Lin LK; Padalkar S; Stanciu LA; Lyubchenko YL; Kirik D; Rochet JC
Mol Neurodegener; 2020 Sep; 15(1):49. PubMed ID: 32900375
[TBL] [Abstract][Full Text] [Related]
4. Sequestration of synaptic proteins by alpha-synuclein aggregates leading to neurotoxicity is inhibited by small peptide.
Choi MG; Kim MJ; Kim DG; Yu R; Jang YN; Oh WJ
PLoS One; 2018; 13(4):e0195339. PubMed ID: 29608598
[TBL] [Abstract][Full Text] [Related]
5. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
[TBL] [Abstract][Full Text] [Related]
6. Role of Parkinson's Disease-Linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by 3,4-Dihydroxyphenylacetaldehyde.
Lima VA; do Nascimento LA; Eliezer D; Follmer C
ACS Chem Neurosci; 2019 Jan; 10(1):690-703. PubMed ID: 30352158
[TBL] [Abstract][Full Text] [Related]
7. The effects of the novel A53E alpha-synuclein mutation on its oligomerization and aggregation.
Lázaro DF; Dias MC; Carija A; Navarro S; Madaleno CS; Tenreiro S; Ventura S; Outeiro TF
Acta Neuropathol Commun; 2016 Dec; 4(1):128. PubMed ID: 27938414
[TBL] [Abstract][Full Text] [Related]
8. Different Effects of α-Synuclein Mutants on Lipid Binding and Aggregation Detected by Single Molecule Fluorescence Spectroscopy and ThT Fluorescence-Based Measurements.
Ruf VC; Nübling GS; Willikens S; Shi S; Schmidt F; Levin J; Bötzel K; Kamp F; Giese A
ACS Chem Neurosci; 2019 Mar; 10(3):1649-1659. PubMed ID: 30605594
[TBL] [Abstract][Full Text] [Related]
9. Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form.
Collier TJ; Srivastava KR; Justman C; Grammatopoulous T; Hutter-Paier B; Prokesch M; Havas D; Rochet JC; Liu F; Jock K; de Oliveira P; Stirtz GL; Dettmer U; Sortwell CE; Feany MB; Lansbury P; Lapidus L; Paumier KL
Neurobiol Dis; 2017 Oct; 106():191-204. PubMed ID: 28711409
[TBL] [Abstract][Full Text] [Related]
10. The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells.
Fares MB; Ait-Bouziad N; Dikiy I; Mbefo MK; Jovičić A; Kiely A; Holton JL; Lee SJ; Gitler AD; Eliezer D; Lashuel HA
Hum Mol Genet; 2014 Sep; 23(17):4491-509. PubMed ID: 24728187
[TBL] [Abstract][Full Text] [Related]
11. Alpha synuclein dimers and oligomers are increased in overexpressing conditions in vitro and in vivo.
Marmolino D; Foerch P; Atienzar FA; Staelens L; Michel A; Scheller D
Mol Cell Neurosci; 2016 Mar; 71():92-101. PubMed ID: 26711807
[TBL] [Abstract][Full Text] [Related]
12. Small molecule inhibits α-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons.
Pujols J; Peña-Díaz S; Lázaro DF; Peccati F; Pinheiro F; González D; Carija A; Navarro S; Conde-Giménez M; García J; Guardiola S; Giralt E; Salvatella X; Sancho J; Sodupe M; Outeiro TF; Dalfó E; Ventura S
Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10481-10486. PubMed ID: 30249646
[TBL] [Abstract][Full Text] [Related]
13. Rosmarinic acid protects against MPTP-induced toxicity and inhibits iron-induced α-synuclein aggregation.
Qu L; Xu H; Jia W; Jiang H; Xie J
Neuropharmacology; 2019 Jan; 144():291-300. PubMed ID: 30342981
[TBL] [Abstract][Full Text] [Related]
14. Differential α-synuclein expression contributes to selective vulnerability of hippocampal neuron subpopulations to fibril-induced toxicity.
Luna E; Decker SC; Riddle DM; Caputo A; Zhang B; Cole T; Caswell C; Xie SX; Lee VMY; Luk KC
Acta Neuropathol; 2018 Jun; 135(6):855-875. PubMed ID: 29502200
[TBL] [Abstract][Full Text] [Related]
15. Doxycycline inhibits α-synuclein-associated pathologies in vitro and in vivo.
Dominguez-Meijide A; Parrales V; Vasili E; González-Lizárraga F; König A; Lázaro DF; Lannuzel A; Haik S; Del Bel E; Chehín R; Raisman-Vozari R; Michel PP; Bizat N; Outeiro TF
Neurobiol Dis; 2021 Apr; 151():105256. PubMed ID: 33429042
[TBL] [Abstract][Full Text] [Related]
16. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation.
Lázaro DF; Rodrigues EF; Langohr R; Shahpasandzadeh H; Ribeiro T; Guerreiro P; Gerhardt E; Kröhnert K; Klucken J; Pereira MD; Popova B; Kruse N; Mollenhauer B; Rizzoli SO; Braus GH; Danzer KM; Outeiro TF
PLoS Genet; 2014 Nov; 10(11):e1004741. PubMed ID: 25393002
[TBL] [Abstract][Full Text] [Related]
17. Modelling Ser129 phosphorylation inhibits membrane binding of pore-forming alpha-synuclein oligomers.
Nübling GS; Levin J; Bader B; Lorenzl S; Hillmer A; Högen T; Kamp F; Giese A
PLoS One; 2014; 9(6):e98906. PubMed ID: 24911099
[TBL] [Abstract][Full Text] [Related]
18. Environmental and genetic factors support the dissociation between α-synuclein aggregation and toxicity.
Villar-Piqué A; Lopes da Fonseca T; Sant'Anna R; Szegö ÉM; Fonseca-Ornelas L; Pinho R; Carija A; Gerhardt E; Masaracchia C; Abad Gonzalez E; Rossetti G; Carloni P; Fernández CO; Foguel D; Milosevic I; Zweckstetter M; Ventura S; Outeiro TF
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6506-E6515. PubMed ID: 27708160
[TBL] [Abstract][Full Text] [Related]
19. Toxic effects of human and rodent variants of alpha-synuclein in vivo.
Landeck N; Buck K; Kirik D
Eur J Neurosci; 2017 Feb; 45(4):536-547. PubMed ID: 27893183
[TBL] [Abstract][Full Text] [Related]
20. Molecular characterization of an aggregation-prone variant of alpha-synuclein used to model synucleinopathies.
Masaracchia C; König A; Valiente-Gabioud AA; Peralta P; Favretto F; Strohäker T; Lázaro DF; Zweckstetter M; Fernandez CO; Outeiro TF
Biochim Biophys Acta Proteins Proteom; 2020 Jan; 1868(1):140298. PubMed ID: 31676453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
